We examined cellular membrane fatty acid composition and insulin sensitivity in patients
with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate …

Although it has been reported that bezafibrate influences carbohydrate metabolism, this
possibility has never been properly evaluated in a controlled clinical trial. In this study we …

Objective In hypertriglyceridemic patients, hypertension occurs frequently and may be
associated with hyperinsulinemia and elevated plasma levels of free fatty acids (FFA) …

Synopsis The lipid-modifying profile of bezafibrate is characterised by marked decreases in
elevated triglyceride levels, increases in high density lipoprotein (HDL) cholesterol levels …

The effects of bezafibrate 400 mg day− 1 or placebo administered for 3 months, were
compared in 36 patients with stable Type 1 diabetes and hypercholesterolaemia and/or …

To investigate whether the lowering of triglyceride levels has beneficial effects on glucose
metabolism, we studied 13 nondiabetic men with combined hyperlipidemia (phenotype IIB) …

Non-insuiin-dependent diabetes mellitus (NIDDM) is characterized by hyperglycemia
secondary to increased hepatic glucose output and impaired extrahepatic insulin sensitivity …

Glucose intolerance or diabetes mellitus, hyperlipidemia, obesity and hypertension may
have a close interrelation based on insulin resistance. We selected 28 impaired glucose …

A double-blind, placebo-controlled trial assessed the effect of a slow-release formulation of
bezafibrate (Bezalip Mono, 400 mg daily for 3 months) on lipid profile, glucose homeostasis …

The effects of a sustained-release preparation of bezafibrate (Bezalip Mono) 400 mg once
daily and placebo administered for 3 months were compared in 36 patients with stable type …